Literature DB >> 19680698

"Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws.

Athanassios Kyrgidis, Konstantinos Vahtsevanos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19680698     DOI： 10.1007/s00784-009-0319-8

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN： 1432-6981            Impact factor:   3.573


× No keyword cloud information.
  6 in total

1.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

Authors:  Brett A Lenart; Dean G Lorich; Joseph M Lane
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

2.  More on atypical fractures of the femoral diaphysis.

Authors:  Ernest B K Kwek; Joyce S B Koh; Tet Sen Howe
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

3.  Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

Authors:  Sebastian Hoefert; Inge Schmitz; Andrea Tannapfel; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2009-06-18       Impact factor: 3.573

Review 4.  Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

Authors:  Beatrice J Edwards; Mrinal Gounder; June M McKoy; Ian Boyd; Mathew Farrugia; Cesar Migliorati; Robert Marx; Salvatore Ruggiero; Meletios Dimopoulos; Dennis W Raisch; Seema Singhal; Ken Carson; Eniola Obadina; Steve Trifilio; Dennis West; Jayesh Mehta; Charles L Bennett
Journal:  Lancet Oncol       Date:  2008-12       Impact factor: 41.316

Review 5.  Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.

Authors:  Athanassios Kyrgidis; Stefanos Triaridis; Kostantinos Vahtsevanos; Kostantinos Antoniades
Journal:  Expert Rev Anticancer Ther       Date:  2009-08       Impact factor: 4.512

6.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507
  6 in total
  4 in total

1.  Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.

Authors:  Joo-Young Ohe; Yong-Dae Kwon; Hyeon-Woo Lee
Journal:  Clin Oral Investig       Date:  2011-09-22       Impact factor: 3.573

2.  Denosumab-related osteonecrosis of the jaws.

Authors:  A Kyrgidis; K A Toulis
Journal:  Osteoporos Int       Date:  2010-03-20       Impact factor: 4.507

3.  The facial skeleton in patients with osteoporosis: a field for disease signs and treatment complications.

Authors:  Athanassios Kyrgidis; Thrasivoulos-George Tzellos; Konstantinos Toulis; Konstantinos Antoniades
Journal:  J Osteoporos       Date:  2011-02-16

4.  Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.

Authors:  Loredana Cavalli; Maria Luisa Brandi
Journal:  Ther Clin Risk Manag       Date:  2012-06-11       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.